Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Chemotherapy in Advanced Squamous NSCLC
NCT03629925Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Sep 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in non-small cell lung cancer, squamous cell carcinoma (NSCLC), sponsored by Innovent Biologics. Started Sep 2018; status: completed.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer, squamous cell carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT03629925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629925.